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Pityriasis rubra pilaris (PRP) is a rare papulosquamous 
dermatosis characterized by keratotic follicular papules, 
erythematous scaling, palmoplantar keratoderma and a 
variable degree of erythroderma. Type I PRP, the most 
common adult form, has a typical clinical manifestation, 
and remission in these patients can be achieved within 
3 years. However, the rare type II PRP presents atypical 
features and has a long disease duration. We describe 
here a case of type II PRP associated with rheumatoid 
arthritis (RA) that achieved clinical remission with eta-
nercept therapy. 
CASE REPORT
A 58-year-old woman visited our department with a 5-year history 
of scaly eruptions on her hands, feet, back and buttocks. She also 
reported arthralgia on both fingers and wrists lasting for 2 months. 
Physical examination showed follicular keratotic papules on the 
back and buttocks, in addition to diffuse erythematous desquama-
tive patches on her hands and feet (Fig. 1a and b). Swelling of her 
right wrist joint was also revealed. A skin biopsy on the buttock 
revealed alternating parakeratosis and orthokeratosis, irregular 
acanthosis, focal spongiosis, and lymphocytic exocytosis without 
Munro’s microabscess or the spongiform pustule of Kogoj. The 
biopsy also revealed perivascular lymphocytic infiltration on the 
dermis (Fig. 1e). Based on these clinicopathological findings, the 
patient was diagnosed with PRP. 
Joint space narrowing was observed on the radiocarpal and 
intercarpal joints of the right wrist on X-ray examination. The 
blood examination showed a highly positive rheumatological 
factor and anti-cyclic citrullinated peptide antibody, but she 
was negative for human leukocyte antigen B27. The erythrocyte 
sedimentation rate was 22 mm/h (normal range, 0–20 mm/h) 
and C-reactive protein was 14.4 mg/l (0–5.3 mg/l). She fulfilled 
the RA criteria of 2010 American College of Rheumatology/
European League against Rheumatism classification. 
The patient’s skin lesions were initially treated with oral 
acitretin (10 mg/day) and topical and 
systemic steroid (methylprednisolone 
8 mg/day) for 10 months; however, she 
continued to report burning and itching 
sensation. In the rheumatological clinic, 
sulfasalazine (1,000 mg/day) was started 
for initial 9 months, but it failed to improve 
the arthritis. Methotrexate (12.5 mg/week) 
was administered for following 14 months, 
but the arthritis did not resolve. Finally, the 
patient began to receive subcutaneous in-
jection of 25 mg etanercept twice a week in 
combination with methotrexate (12.5 mg/
week). Clinical remission of skin eruption 
and arthritis was achieved 2 months after 
etanercept therapy. This state was sustained 
for 9 months without any treatment mo-
dification (Fig. 1c and d). However, skin 
lesions recurred one month after cessation 
of etanercept treatment. 
DISCUSSION
Systemic retinoids and/or metho-
trexate have been used as first-line 
therapies for PRP, but many PRP 
cases are refractory to the standard 
treatment. Tumour necrosis factor 
alpha (TNF-α) antagonists, including 
infliximab and etanercept, have been 
reported as effective for patients with 
recalcitrant PRP (1, 2). A total of 8 
cases of PRP treated with etanercept 
have been reported (Table I) (2–6). 
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Fig. 1. The patient showed (a) follicular 
hyperkeratosis on the back and buttocks, 
and (b) erythematous scaling lesions on 
the feet. After 9 months of etanercept 
treatment, (c) clinical remission was 
maintained on back, buttocks, and (d) feet. 
(e) Examination of the biopsy specimen 
revealed alternating parakeratosis and 
orthokeratosis, psoriasiform hyperplasia, 
and superficial perivascular lymphocytic 
infiltration (haematoxylin-eosin staining, 
original magnification × 200).
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Three of these 8 cases were treated with 50 mg of eta-
nercept twice a week as the starting dose. The other 5 
patients continuously received 50 mg once a week or 
25 mg twice a week. However, there was no significant 
difference in the clinical remission or maintenance dose 
between the 2 groups. Our patient showed rapid clinical 
remission within 2 months of treatment with 25 mg of 
etanercept twice a week. 
Eight cases of PRP associated with arthritis have 
been reported. Only one male patient was positive for 
rheumatoid factor, but his features were not sufficient 
to qualify for RA diagnosis (7). As far as we know, this 
is the first case of PRP associated with RA. The concur-
rent treatment of PRP and RA may be challenging (7). 
This case strongly suggests that etanercept is a proper 
treatment for PRP cases associated with RA. In addition, 
the present case is the second example of a patient with 
type II PRP who received etanercept for a long period 
(2). Our patient experienced 9 months of sustained 
clinical remission and relapse after drug-withdrawal, 
which is similar to a previous case.
While the pathogenesis of PRP is not certain, an im-
munological response to antigenic triggers has been 
proposed (8). The clinical response to etanercept in PRP 
patients suggests that TNF-α-related inflammatory reac-
tions (e.g. interleukin-1, -6, and -8) are involved in the 
pathogenesis of PRP. To understand the role of etanercept 
in PRP treatment, further studies are needed that investi-
gate which cytokines or immune cells change in PRP skin 
after anti-TNF-α treatment. It is not yet known whether 
etanercept modifies the chronic course of PRP. 
In conclusion, etanercept should be considered an 
effective treatment option for chronic PRP, because it 
can induce long-term remission.
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Table I. Previously published cases and the present case of pityriasis rubra pilaris (PRP) treated with etanercept
No.
Sex/age 
years
Type of 
PRP Treatment before etanercept 
Time to 
remission 
months
Follow-up 
months Initial dose
Associated 
disease References
1 M/55 I Systemic retinoids, systemic steroid 
Cy and topical steroid,
Unknown 7 50 mg ×2/week None Davis et al., 2007 (3)
2 F/16 III Topical steroid, topical retinoids, and 
calcipotriene
4 6 50 mg ×2/week None Cox et al., 2008 (4)
3 M/37 I Systemic retinoids and Cy 3 6 50 mg ×2/week None Sekin et al., 2008 (5)
4 M/59 I Systemic retinoids, systemic steroid 
and Cy
1 16 50 mg/week None Garcovich et al., 2010 (2)
5 M/56 I Systemic retinoids 2 15 50 mg/week None Garcovich et al., 2010 (2)
6 M/59 I Systemic retinoids and Cy 2 15 50 mg/week None Garcovich et al., 2010 (2)
7 M/40 II Systemic retinoids, Cy and PUVA 3 24 50 mg/week None Garcovich et al., 2010 (2)
8 F/30 I Systemic retinoids and topical steroid 2 9 25 mg ×2/week None Guedes et al., 2011 (6)
9 F/58 II Systemic retinoids, systemic steroids, 
sulfasalazine and methotrexate
2 10 25 mg ×2/week RA Present case
None of the cases had complications.
Cy: Cyclosporine; PUVA: psoralen plus ultraviolet A phototherapy; RA: rheumatoid arthritis.
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